Onco hires U.S. bank as capital market adviser

Mr. Thomas O'Shaughnessy reports ONCO-INNOVATIONS ENGAGES INVESTMENT BANK TO PURSUE NASDAQ CROSS-LISTING AND POTENTIAL CONCURRENT EQUITY OFFERING Onco-Innovations Ltd. has engaged a U.S. investment bank to serve as its capital market adviser in connection with the company's intention to pursue a potential cross-listing of its common shares on Nasdaq Stock Market LLC and to evaluate and structure a potential concurrent equity financing. The structure and terms of the contemplated financing have not yet been finalized. This engagement forms part of the company's continuing evaluation of options intended to support long-term corporate development. The advisory mandate will include analysis and planning related to listing requirements, regulatory considerations, and the capitalization strategies necessary to facilitate the potential U.S. cross-listing and concurrent financing. The company notes that no assurance can be given that a cross-listing or concurrent financing will be completed, and any such listing would remain subject to meeting applicable regulatory, governance and exchange requirements. About Onco-Innovations Ltd. Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide licence to patented technology that targets solid tumours. We seek Safe Harbor.